StreetInsider.com News Articles

Stifel Reiterates Hold Rating on TransMedics Group (TMDX)

Thu, 15 Oct 2026 09:46:03 -0400

Stifel analyst Thomas Stephan reiterated a Hold rating and $65.00 price target on TransMedics Group (NASDAQ: TMDX).

The analyst commented, "We estimate TMDX flight data points to 3Q26 total revenue of $185M-$190M, nicely above Street’s $178M—and while we expect a beat-and-raise on the upcoming print, we sense investors also anticipate this.Importantly, 3Q26 market growth and flight-implied OCS US volumes suggest TMDX’s rate of y/y share gains may have reaccelerated following softer share trends in 1H26.Although share gains are encouraging and incremental ENHANCE/ DENOVO revenues are on the come, our competition-related TMDX cautiousness is longer-term in nature: our XVIVO heart diligence was

TransMedics Group (TMDX) PT Lowered to $110 at Baird

Thu, 15 Oct 2026 07:22:50 -0400

Baird analyst David Rescott lowered the price target on TransMedics Group (NASDAQ: TMDX) to $110.00 (from $122.00) while maintaining a Outperform rating.

TransMedics Group (TMDX) PT Lowered to $94 at Canaccord

Tue, 13 Oct 2026 06:54:15 -0400

Canaccord analyst Jason Mills lowered the price target on TransMedics Group (NASDAQ: TMDX) to $94.00 (from $95.00) while maintaining a Buy rating.

Barclays Starts TransMedics Group (TMDX) at Overweight

Tue, 06 Oct 2026 16:26:21 -0400

Barclays initiates coverage on TransMedics Group (NASDAQ: TMDX) with a Overweight rating and a price target of $120.00.

For an analyst ratings summary and ratings history on TransMedics Group click here. For more ratings news on TransMedics Group click here.

Shares of TransMedics Group closed at $82.99 yesterday.

Form 3 TransMedics Group, Inc. For: Sep 21 Filed by: Araujo Fernando N.

Tue, 29 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260929/27122675.html

Form 4 TransMedics Group, Inc. For: Sep 11 Filed by: Weill David

Mon, 14 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260914/27058804.html

Needham Reiterates Buy Rating on TransMedics Group (TMDX)

Fri, 11 Sep 2026 05:55:47 -0400

Needham analyst Mike Matson reiterated a Buy rating and $106.00 price target on TransMedics Group (NASDAQ: TMDX).

The analyst comments "After the market closed on Thursday, TMDX announced that it had appointed Fernando Araujo as CFO. Araujo has more than 20 years of experience in public company finance roles at GE Healthcare (GEHC - Not Covered), General Electric (GE - Not Covered), and 3M (MMM - Not Covered). His most recent role was CFO of GE HealthCare's Advanced Imaging Solutions, a $16B segment. Gerardo Hernandez, formerly CFO, will transition to Commercial Strategic Advisor, LATAM where he will lead TMDX's expansion into

Form 8-K TransMedics Group, Inc. For: Sep 10

Thu, 10 Sep 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260910/27049018.html

TransMedics names new CFO and reiterates 2026 revenue guidance

Thu, 10 Sep 2026 16:05:30 -0400

TransMedics Group, Inc. (Nasdaq: TMDX) announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026. Araujo succeeds Gerardo Hernandez, who will move to a Commercial Strategic Advisor role focused on Latin America expansion.

Araujo brings more than 20 years of public-company finance experience. Most recently, he served as CFO of GE HealthCare's Advanced Imaging Solutions segment, a $16 billion business. He previously held the role of Corporate Finance CFO at GE HealthCare and served as Senior Vice President of Finance for Enterprise Operations at 3M. Earlier in his career, he spent 17 years at General Electric in

TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook

Thu, 10 Sep 2026 16:05:00 -0400

ANDOVER, Mass., Sept. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026. Mr. Araujo brings more than 20 years of public-company finance leadership at GE HealthCare, General Electric, and 3M to support the Company's next phase of global growth. He succeeds Gerardo Hernandez, who will transition to Commercial Strategic Advisor, LATAM to lead TransMedics' expansion into Latin America. Concurrent with

TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook

Thu, 10 Sep 2026 16:05:00 -0400

Form 4 TransMedics Group, Inc. For: Aug 17 Filed by: TOBIN JAMES R

Mon, 17 Aug 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260817/26938559.html

Form 4 TransMedics Group, Inc. For: Aug 17 Filed by: TOBIN JAMES R

Mon, 17 Aug 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260817/26938559.html

TransMedics Group (TMDX) PT Lowered to $77 at UBS

Wed, 05 Aug 2026 09:37:10 -0400

UBS analyst Patrick Wood lowered the price target on TransMedics Group (NASDAQ: TMDX) to $77.00 (from $80.00) while maintaining a Neutral rating.

TransMedics Group (TMDX) PT Lowered to $65 at Stifel

Wed, 05 Aug 2026 08:24:25 -0400

Stifel analyst Thomas Stephan lowered the price target on TransMedics Group (NASDAQ: TMDX) to $65.00 (from $80.00) while maintaining a Hold rating.

TransMedics Group (TMDX) PT Lowered to $92 at JPMorgan

Wed, 05 Aug 2026 08:17:20 -0400

JPMorgan analyst Allen Gong lowered the price target on TransMedics Group (NASDAQ: TMDX) to $92.00 (from $100.00) while maintaining a Neutral rating.

TransMedics Group (TMDX) PT Lowered to $100 at Piper Sandler

Wed, 05 Aug 2026 07:03:42 -0400

Piper Sandler analyst Matt O'Brien lowered the price target on TransMedics Group (NASDAQ: TMDX) to $100.00 (from $120.00) while maintaining a Overweight rating.

Form 10-Q TransMedics Group, Inc. For: Jun 30

Tue, 04 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260804/26866639.html

Form 10-Q TransMedics Group, Inc. For: Jun 30

Tue, 04 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260804/26866639.html

Form 8-K TransMedics Group, Inc. For: Aug 04

Tue, 04 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260804/26866139.html

Form 8-K TransMedics Group, Inc. For: Aug 04

Tue, 04 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260804/26866139.html

TransMedics Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 16:05:00 -0400

ANDOVER, Mass., Aug. 4, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2026.